MedTrace Logo

Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial

NCT07103382 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-09-05

No results posted yet for this study

Summary

To explore the safety and efficacy of attapulgite in the treatment of obese individuals or overweight/obese individuals with type 2 diabetes.

Conditions

Interventions

DIETARY_SUPPLEMENT

Attapulgite

Participants were administered daily attapulgite (2.5 g) for a duration of 12 weeks.

DIETARY_SUPPLEMENT

Placebo

Participants were administered daily maltodextrin (2.5 g) for a duration of 12 weeks.

Sponsors & Collaborators

  • Second Xiangya Hospital of Central South University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-26
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07103382 on ClinicalTrials.gov